Miao W's group have reported that METTL3 were able to promote osteosarcoma progression by regulating the m6A level of lymphoid enhancer-binding factor 1 (LEF1), and silencing of METTL3 contributed to decrease in m6A methylation and mRNA level of LEF1, thereby suppressing Wnt/β-catenin signaling pathway.[45] Thus it is speculated that METTL3 may associate with osteosarcoma prognosis via Wnt/β-catenin signaling pathway. Here, LEF1 is linked to osteosarcoma.